Observational studyHerz2025
Timing of RAS blocker administration and long-term cardiovascular outcomes in STEMI patients.
Observational study in Herz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenin-angiotensin system (RAS) blockers constitute a cornerstone in the management of patients with cardiovascular disease. However, the relationship between the administration time of these drugs during the day and cardiovascular events is not yet fully elucidated. We aimed to examine the relationship between the administration time of RAS blockers during the day and long-term cardiovascular outcomes in patients with ST-segment elevation myocardial infarction (STEMI).
methodsA total of 701 patients who were admitted to our hospital between 2018 and 2020 with STEMI and underwent primary percutaneous coronary intervention (PCI) were included in this single-center, retrospective, observational study. Primary endpoints were acute heart failure (AHF), nonfatal myocardial infarction, major adverse cardiovascular events (MACE), and long-term mortality. Patients were divided into two group according to the administration of RAS blockers in the morning (06:00-10:00) or evening (20:00-00:00).
resultsThe mean age of the patients was 57.5 ± 11.9 years and 75.9% were male. After discharge, 485 patients were taking RAS blockers in the morning and 216 patients were taking them in the evening. There was a significantly higher rate of AHF, nonfatal myocardial infarction, MACE, and death in the group taking RAS blockers in the morning compared to the group taking them in the evening (p < 0.01, p = 0.02, p < 0.01, p < 0.01, respectively).
conclusionRoutine administration of RAS blockers in the evening rather than in the morning led to a remarkable decrease in the occurrence of AHF, nonfatal myocardial infarction, MACE, and mortality.
Indexed as
Identifiers
40522354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.